Acquisition of Cytokine
in TIMELINES on
Acquisition of Cytokine PharmaSciences Inc. (CPSI) and its subsidiary, Controlled Therapeutics Scotland (CTS). The new entity called Ferring Controlled Therapeutics…
0
0
-
Read more
-
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (PENTASA®) in active ulcerative colitis
in PRESS RELEASE 2011 onRead moreResults of a new study 1 presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate…
-
Ferring Pharmaceuticals acquires Cytokine PharmaSciences Inc.
in PRESS RELEASE 2011 onRead moreFerring Pharmaceuticals (Ferring) announced today that it has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its…
-
The untold impact of childhood bedwetting in later life
in PRESS RELEASE 2011 onRead moreNew data, presented today at the International Continence Society (ICS) congress in Glasgow1, suggest that bedwetting…
-
New research reveals night-time toilet trips are not a trivial problem
in PRESS RELEASE 2011 onRead moreNew data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…
-
New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology
in PRESS RELEASE 2011 onRead moreNew data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…
-
MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles
in PRESS RELEASE 2011 onRead moreNew data1, presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…
-
Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer
in PRESS RELEASE 2011 onRead moreRecent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…
-
SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland
in PRESS RELEASE 2011 onRead moreToday’s decision by the Scottish Medicines Consortium (SMC) (www.scottishmedicines.org.uk) to accept the use of FIRMAGON…